News · 26 weeks55+25%
2026-03-012026-08-23
Mix2590d
- Other8(32%)
- SEC Filings8(32%)
- Insider5(20%)
- Earnings4(16%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Verastem Inc.SCHEDULE 13G - Verastem, Inc. (0001526119) (Subject)
- SECVerastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- SECSEC Form 10-Q filed by Verastem Inc.10-Q - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesAVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from Oberland fa
- INSIDERPresident and CEO Paterson Dan sold $7,565 worth of shares (1,302 units at $5.81), decreasing direct ownership by 0.22% to 589,940 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- PRVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal CancerTARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the combination of VS-7375 with cetuximab and chemotherapy for frontline treatment of metastatic colorectal cancer KRAS G12D is one of the most common KRAS variants in metastatic colorectal cancer, occurring in approximately 15% of patients All three TARGET-D registration-directed Phase 2 clinical trials now enrolling following first-patient dosing across pancreatic, colorectal, and lung cancers Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new m
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- PRVerastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceut
- PRVerastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung CancerTARGET-D 202 to evaluate VS-7375 as monotherapy at the RP2D of 900mg in patients with previously treated advanced non-small cell lung cancer A cohort in TARGET-D 202 will also evaluate VS-7375 in non-small cell lung cancer patients with asymptomatic untreated brain metastases Approximately 5% of patients with non-small cell lung cancer harbor a KRAS G12D mutation, yet no therapies specifically targeting KRAS G12D are FDA-approved for this patient population Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 202 Phase 2
- PRVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $4.10, the closing price of Verastem Oncology’s common stock as reported by Nasdaq on July 1, 2026. A t
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- INSIDERPresident and CEO Paterson Dan sold $87,241 worth of shares (20,871 units at $4.18), decreasing direct ownership by 3% to 591,242 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERChief Financial Officer Calkins Daniel sold $17,089 worth of shares (4,089 units at $4.18), decreasing direct ownership by 3% to 117,238 units (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- SECVerastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- PRVS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid TumorsBroad anti-tumor activity observed with VS-7375 across dose levels in multiple solid tumors, including pancreatic, colorectal, and lung cancers Early evidence of anti-tumor activity with either anti-EGFR therapy or standard-of-care chemotherapy supports broad development strategy including combinations Favorable safety and tolerability profile characterized by predominately low-grade gastrointestinal adverse events that attenuate after cycle 1; favorable tolerability in combination regimens Verastem and Erasca announce their intent to evaluate VS-7375 in combination with ERAS-0015, Erasca’s investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors Company to
- SECVerastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Verastem, Inc. (0001526119) (Filer)
- PRVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis 6-month overall survival rate was 86%; follow-up continues and survival data continue to mature Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). KRAS is mutated in more than 90% of pancreatic cancers, mak
- PRVerastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic CancerTARGET-D 201 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab for second-line treatment of metastatic pancreatic cancer A cohort in TARGET-D 201 will also evaluate the combination of VS-7375 and cetuximab for frontline treatment of metastatic pancreatic cancer VS-7375 previously granted FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer KRAS G12D is the most common KRAS mutation in pancreatic cancer, occurring in approximately 40% of patients, and is often associated with poorer prognosis Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pa
- PRVerastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical ProgramFeaturing updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor conference call and webcast on Tuesday, June 23 at 4:30 pm ET to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D clinical program and updated preliminary data from the Phase 1/2 TARGET-D 101 dose escalation and dose expansion trial evaluating VS-7375 alone and in combination in patients wi
- PRVerastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026 Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC) FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas
- SECSEC Form S-8 filed by Verastem Inc.S-8 - Verastem, Inc. (0001526119) (Filer)
- INSIDERDirector Bailey Michael P was granted 108,000 shares (SEC Form 4)4 - Verastem, Inc. (0001526119) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bailey Michael P3 - Verastem, Inc. (0001526119) (Issuer)
- SECSEC Form 144 filed by Verastem Inc.144 - Verastem, Inc. (0001526119) (Subject)
- PRVerastem Oncology to Present at Jefferies Healthcare ConferenceVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and
VSTM FAQ
7 questionsWhat does Verastem Inc. do?
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal...Where does VSTM stock trade?
Verastem Inc. (VSTM) is listed on NASDAQ.What sector and industry is VSTM in?
Verastem Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Verastem Inc. go public?
Verastem Inc. (VSTM) completed its IPO in 2012.What are analysts saying about VSTM?
Verastem Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1900.00 price target on 2026-03-12. Recent price targets range from $1000.00 to $2700.00.What companies are similar to VSTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VSTM side-by-side with any of them on Quantisnow.How can I track VSTM on Quantisnow?
Quantisnow aggregates Verastem Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VSTM to receive live email and push alerts on every new disclosure.